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ABSTRACT 
Background: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing 
hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and 
often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs 
administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.  
Methods: This study was a retrospective review of records of patients who received allogeneic HSCT in the 
Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, between August 
2009 and August 2010.  
Results: Sixty (73.1%) patients consist of 41 men (68.3%) with mean age of 26.3 (± 1.2) years received 
allogeneic HSCT. Patients received prophylaxis with fulconazole however; in 28 patients (46.7%) it was 
switched to low dose amphotericin B. Fifteen patients (25%) received treatment with antifungal agents. 
Amphotericin B was the empiric agent administered. In 3 patients treatment was switched to voriconazole. 
Neither positive culture nor direct microscopic evidence was available from the obtained specimen. Only in one 
patient the result of serum galactomannan assay was positive. There were no significant differences in 
neutropenia duration (P value: 0.54), length of hospital stay (P value: 0.27) and number of patients 
developed graft versus host disease (P value: 0.07) between patients received antifungal agents with those 
who did not receive treatment.  
Conclusion: In this study HSCT recipients received antifungal agents for prophylaxis. Twenty five percent of 
patients received treatment with antifungal agents empirically. Improvement in diagnosis of these infections 
can be helpful and lead to targeted therapy. We suggest larger prospective trials for better assessment of 
antifungal agent administration.  
 
KEY WORDS: Antifungal agents, Peripheral blood stem cell transplantation, Retrospective Studies, 
Amphotericin B 
 
INTRODUCTION  
   Hematopoietic stem cell transplantation (HSCT) is 
an effective treatment modality, for a variety of 
hematologic malignancies.1 Despite improvement in 
the prophylaxis and treatment strategies2 and 
supportive care measures,3 infection still is 
considered as a substantial cause of morbidity and 
mortality in patients undergoing HSCT,4, 5 By the 
advances achieved in the control of bacterial 
infections after HSCT, invasive fungal infections 
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(IFIs) are chief infectious complications in these 
patients.6 The leading causes of infection in this 
category are Candida and Aspergillus species.7 
Additionally, infections with less common fungi like 
Fusarium and Trichosporon species have been 
reported in this patient population.8 The incidence 
of IFI after allogeneic HSCT is estimated to be 10% 
to 25% in high-risk patients.9 The mortality rate of 
these infections may reach to 70% to 90%.10  
   There are many risk factors that have been 
evaluated for the development of IFI following 
HSCT. Some of them are neutropenia duration, 
receiving glucocorticoids, donor type, age,11 
underlying disease,8, 11 graft-versus-host disease 
(GVHD),8,11,12 organ dysfunction (renal, hepatic, or 
respiratory failure), hyperglycemia, cytomegalovirus 
or HIV infections,8 the function of immune system,8, 
9, 13 breakdown of the gut mucosa due to 
chemotherapy and radiation therapy,8 use of 
indwelling devices9, 13 and iron overload.8, 9, 13  
   Routinely four strategies including prophylactic, 
empiric, preemptive, and targeted therapy are 
applied for the management of fungal infections.14 
As a common practice, high risk patients receive 
prophylaxis against fungal infections.14 For 
prophylaxis against Candida infections in patients 
undergoing HSCT, fluconazole has been 
administered during the neutropenic period.15 
Whenever possible to identify the infectious fungi, 
targeted treatment can be implemented.14 
According to EORTC/MSG consensus group, the 
proved diagnosis of fungal infection in a patient 
with findings consistent with an endemic mycosis 
needs at least positive culture obtained from blood 
or the affected site or evidences from 
histopathology or direct microscopic observation.16 
However, the diagnosis of fungal infections is 
difficult due to several factors. One of them is the 
lack of diagnostic facilities for simple and early 
detection.17 Moreover, according to IDSA guideline 
for neutropenic patients with 5 days of persistent 
fever after the initiation of broad spectrum 
antibiotics, in whom no specific cause has been 
determined; starting empiric antifungal treatment 
can be considered.18 Despite the advances achieved 
in the diagnosis and treatment of fungal infections, 
unfortunately there are still centers in which the 
proved diagnosis of fungal infections cannot be 
made and other strategies have been used for the 
treatment of suspected and less well documented 
infections.  
   Since the introduction of amphotericin B in 
1958,19 the availability of lipid-based formulations 
of amphotericin B, echinocandins and extended-
spectrum triazoles7 were major advances towards 
the treatment of fungal infections and provided the 
clinicians with wider treatment options. Nowadays 
these agents are prescribed increasingly for the 
treatment of fungal infections due to increased 
number of immune compromised and critically ill 
patients.20  
   In Iran, different studies have addressed the 
prevalence of IFIs in the setting of solid organ 
transplantation.21-23 But to the best of our 
knowledge, there is no data available on the 
prevalence of antifungal drugs administration in 
HSCT setting. So the aim of this study was to assess 
the prevalence of treatment with antifungal agents 
in allogeneic HSCT recipients. 
 
MATERIALS AND METHODS 
   In this study, we present the retrospective review 
of records of patients who received allogeneic HSCT 
in the Hematology-Oncology, Bone Marrow 
Transplantation center at Shariati Hospital in 
Tehran, Iran, between August 2009 and August 
2010. The study protocol was approved by the ethic 
committee of the institution. Source of stem cells 
for HSCT in all patients were peripheral blood. 
Patients with haploidentical or autologous HSCT 
were excluded from the study. Patients received 
different conditioning regimens according to the 
underlying disease and based on the hospital 
protocols. None of the patients in this center 
received total body irradiation (TBI) as a part of 
conditioning regimen. 
 
Definitions 
   The day of the HSCT procedure was considered to 
be day 0 and the days after and before that, were 
named to be + and – respectively. The time 
between HSCT and hospital discharge was referred 
to as the recovery period.  
   Fever was defined as a temperature ≥ 38.3 ⁰C. 
Engraftment was considered when ANC counts of ≥ 
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500 103/L and platelet counts of ≥ 20000103/L 
were achieved for three consecutive days without 
transfusion. 
 
Supportive Cares and Prophylactic Measures 
   All patients were hospitalized in isolated rooms 
and received the same care. Patients’ nutrition was 
supported parentally. Phenytoin was administered 
to patients receiving conditioning regimens 
containing busulfan for seizure prophylaxis 
additionally; patients received prophylaxis against 
nausea and vomiting. Transfusion of blood and 
platelet were ordered according to patients’ 
condition. GVHD prophylaxis consisted of 
cyclosporine and low dose methotrexate in patients 
who received allogeneic HSCT.  
 
Infection Prophylaxis and Treatment 
   All patients received low dose acyclovir on 
admission which continued throughout 
hospitalization for prophylaxis of Herpes Zoster. 
Also patients received cotrimoxazole for the 
prevention of Pneumocystis Carinii infection. CMV 
antigen testing was performed weekly and positive 
cases were treated accordingly. Additionally, 
patients received antifungal prophylaxis. 
Management of fever in neutropenic patients was 
according to the guideline of Infectious Diseases 
Society of America (IDSA) on “the use of 
antimicrobial agents in neutropenic patients with 
cancer” 18. For neutropenic febrile patients an 
appropriate blood cultures were obtained to 
determine the source of infection before initiation 
of broad spectrum antibiotics empirically. If the 
fever episode was persistent after 48 hours and no 
etiology for the infection was identiﬁed, 
vancomycin was added to the previous medications. 
Whenever fever continued for more than 5 days 
after initiating antibiotics and there was no deﬁnite 
source of infection, empiric antifungal treatment 
was started. Therapy was then modified 
accordingly.  
 
Statistical Analysis 
   Cross-checking of extracted data with the original 
data sheets and patients charts was done 
rigorously. Tables, absolute frequency, percentage, 
median, mean, standard error of the mean, 
maximum and minimum values were used to 
summarize different types of data as appropriate. 
   To determine the relationship between 
distributions of demographic or clinical covariates in 
allogeneic HSCT patients whether or not receiving 
treatment with antifungal agents, we used chi-
square test or Fisher's exact test for categorical 
data, independent sample t-test for quantitative 
data with parametric distributions, and Mann-
Whitney U test for quantitative data with non-
parametric distribution. All the analyses were 
performed using SPSS version 17.0 (SPSS Inc., 
Chicago, IL, USA). Statistical significance was set at 
p<0.05 to reject the null hypothesis. 
 
RESULTS 
   During the one-year study period, eighty two 
patients were admitted to the ward. Sixty (73.2%) 
patients received allogeneic HSCT. Patients 
consisted of 41 men (68.3%) and 19 women (31.7%) 
with mean age of 26.3 (± 1.2) years. Thirty two 
patients (53.3%) received HSCT due to hematologic 
malignancies; the rest of them received HSCT 
because of other underlying diseases such as 
thalassemia, aplastic anemia and a few other 
infrequent diseases. In fact thalassemia was the 
most prevalent condition (26.7%) leading to HSCT 
followed by acute myeloid leukemia (AML) (23.3%) 
in this set of patients. Median time to engraftment, 
median duration of neutropenia and median 
recovery period were 12 (range: 9-32), 8 (range: 2-
22) and 21 (range: 12-48) days respectively. 
Additionally median length of hospitalization was 30 
(21-55) days.  
 
Antifungal Administration 
   All patients (except one) in this study received 
antifungal prophylaxis with fulconazole 100 mg 
twice daily orally. One patient was under treatment 
with posaconazole and amphotericin B before 
hospitalization. In 28 patients (46.7%) the 
prophylaxis of fungal infection was switched from 
oral fluconazole to low dose intravenous 
amphotericin B (0.3 mg/kg/day) due to the severity 
of mucositis which made the oral administration of 
medications impossible for the patients.  
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   Among all of allogeneic HSCT recipient in this 
study, 15 patients (25%) received treatment with 
systemic antifungal medications. The prophylactic 
agent was discontinued upon the initiation of the 
treatment. Among patients under prophylaxis with 
amphotericin B, in 4 patients the dose of 
amphotericin B increased to the therapeutic dose 
due to the suspected infections. The median 
duration of antifungal treatment for patients who 
received the therapeutic doses of amphotericine B 
was 10 (2-23) days.  
   Neither positive cultures nor histopathologic or 
direct microscopic evidences were available from 
the specimen obtained from patients. However, in 
one patient the result of serum galactomannan 
assay was positive.  
   Empiric treatment with antifungal agent was 
initiated with amphotericin B in 14 patients 
however, later in 3 patients; treatment was 
switched from amphotericin B to voriconazole due 
to the suspicious of aspergillosis infection.  
  Characteristics of HSCT recipients and the frequent 
regimens used for pre transplantation conditioning 
are summarized in Table 1 and Table 2 respectively. 
 
Table1. Characteristic of Allogeneic HSCT Recipients who Received Treatment with Antifungal Agents and Those who did not Receive 
Treatment 
Characteristics of HSCT recipients 
Patients who did not receive 
treatment with antifungal 
agents (n=45) 
Patients who received  treatment 
with antifungal agents (n=15) 
P-values 
Male Gender (%) 30 (66.7%) 11 (73.3%) 0.44 
Median age year  (range) 23 (14-53) 24 (13-47) 
0.99 
Mean age year ± standard error 26.3 ± 1.4 26.3± 2.4 
Underlying diseases n (%) 
Thalassemia 13 (28.9%) 3 (20.0%)  
AML 11 (24.4%) 3 (20.0%)  
ALL 8 (17.8%) 4 (26.7%)  
AA 5 (11.1%) -  
CML 3 (6.7%) -  
MM 2 (4.4%) 1 (6.7%)  
MDS 1 (2.2%) 2 (13.3%)  
Other conditions † 2 (4.4) 2 (13.3%)  
Median engraftment time, day  (range) 12.5 (9-20) 12  (10-32) 0.6 ‡ 
Median fever duration day (range) 6 (1-27) 8 (2-25) 0.09‡ 
Median infused CD34+ (106/kg) (range) 4.9 (1-8.9) 5.2 (2.0-12.1) 0.66‡ 
Median neutropenia duration day (range) 7 (0-15) 8 (0-22) 0.54‡ 
Median length of hospitalization day (range) 29 (21-47) 31 (22-55) 0.27‡ 
Median recovery period day (range) 20 (12-40) 22 (15-48) 0.18‡ 
Status of underlying disease at HSCT n (%)                                                                                                                                                0.23 
CR1 15 (33.3%) 4 (26.7%) 
 
CR2 9 (20.0%) 3 (20.0%) 
CR3 5 (11.1%) 5 (11.1%) 
Not applicable 16 (35.6%) 3 (20.0%) 
AML: Acute Myelogenous Leukemia, ALL: Acute Lymphoblastic Leukemia, AA: Aplastic Anemia, CML: Chronic Myeloid Leukemia, MM: Multiple Myeloma, MDS: 
Myelodysplastic syndrome, CR: Complete Remission  
†Other conditions consisted of one patient with the diagnosis of paroxysmal nocturnal hemoglobinuria and one patient with myelofibrosis in each group   
‡ P values are based on Mann-Whitney U test 
 
Table2. Frequent Conditioning Regimens Used for Allogeneic HSCT in Patients who Received Treatment with Antifungal Agents and 
Those who did not Receive Treatment 
Conditioning regimen 
(underlying diseases ) 
Patients who did not receive  
treatment with antifungal agents 
Patients who received treatment 
with antifungal agents 
Busulfan/Cyclophosphamide 22 11 
Busulfan/Fludarabine/ Antithymocyte globulin 11 - 
Busulfan/Cyclophosphamide/Antithymocyte globulin 3 2 
Cyclophosphamide  /Antithymocyte globulin 5 - 
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GVHD 
   Among patients received allogeneic HSCT, acute 
GVHD appeared in 32 (53.3%) patients and the most 
frequent involved site was skin (46.9%). Table 3 
shows the acute GVHD Severity and the affected 
organs in patients who underwent treatment with 
antifungal agents and those who did not receive 
antifungal treatment. 
 
Table3. Severity of Acute GVHD and the Involved Site in HSCT Recipient 
 
Patients who did not receive treatment with 
antifungal agents (n=45) 
Patients who received  treatment with 
antifungal agents (n=15) 
P value † 
Presence of GVHD (%) 21 (46.7%) 11 (73.3%) 0.07 
GVHD severity grade n (%) 0.26 
I 12 (57.1%) 3 (27.3%)  
II 5 (23.8%) 5 (45.5%)  
III 4 (19.0%) 3 (27.3%)  
Organ involved n (%) 0.02 
Skin 13 (61.9%) 2 (18.2%)  
Gastrointestinal tract 3 (14.3%) 1 (9.1%)  
Skin and gastrointestinal tract 5 (23.8%) 8 (72.7%)  
† P values are based on Chi-square test  
 
DISCUSSION 
   Hematology-oncology wards and intensive care 
units are among the highest consuming antifungal 
agents in hospitals.24 It is important to know the 
data about antifungal agents prescribed in these 
wards. In this retrospective study we evaluated the 
prevalence of antifungal medications administered 
to patients receiving HSCT during early post 
transplant period in a referral hospital in Tehran.  
   During this one-year study almost all patients 
received fluconazole for the prophylaxis of fungal 
infections; however, in 28 patients the switch to 
intravenous antifungal prophylaxis was inevitable 
and they received low dose amphotericin B for this 
purpose. Although due to the potential toxicity, 
amphotericin B was more used as a treatment 
option rather than prophylaxis,25 the approach of 
using this drug as a prophylactic agent goes back to 
the studies conducted in 1990s.26 In a prospective 
randomized trial, Koh et al., compared the efficacy 
of prophylactic use of fluconazole and low-dose 
amphotericin B against fungal infections in 
recipients of HSCT. Overall, the study showed that 
the incidence of proven, suspected or superficial 
fungal infections was not significantly different 
between the two groups.27 Other studies also 
evaluated using liposomal amphetamine B for 
prophylaxis.28-30  
   Varieties of antifungal agents are now used for 
prophylaxis in different centers. For example 
Martino et al., evaluated 395 recipients of 
allogeneic HSCT in Spain and reported that 73% of 
patients received fluconazole, 17% itraconazole and 
4% amphotericin B for prophylaxis and 6% did not 
receive any antifungal agent for this purpose.11 
None of the patients in our study received 
itraconazole for prophylaxis. Also there are reports 
of poor tolerability of itraconazole.31 For example in 
a cohort of 549 high risk haematology and HSCT 
recipients Barnes et al., found that itraconazole was 
poorly tolerated for prophylaxis and therapeutic 
serum levels were achieved only in 70% of 
patients.32  
   Fifteen patients (25%) in our study received 
antifungal medications due to the suspected IFIs. 
None of the patients received azoles (neither 
fluconazole nor itraconazole) for the therapeutic 
purposes. The empiric antifungal drug administered 
for patients in our study was amphotericin B. 
However, in a study on sales data of five university 
hospitals in Germany, de With et al., showed that 
amphotericin B consumption decreased during the 
period of 2001-2003 in the hematology-oncology 
wards which was primarily attributed to increase in 
voriconazole administration.24 Additionally, as it is 
expected the pattern of empirical antifungal 
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administration is variable in different centers. For 
example in a retrospective study of four-year 
antifungal prescription in hematologic patients, 
Chan et al., reported that echinocandins were 
accounted for 62% of all antifungal 
administrations.33 In contrast none of the patient in 
our study received this category of antifungal 
agents. This was probably due to the unavailability 
of micafungin, and anidulafungin and restricted 
availability of caspogungin in Iran. Additionally, the 
cost of the latter drug was not covered by the 
medication insurance systems at the time of the 
study. In a meta-analysis, Goldberg et al., compared 
empirical or preemptive antifungal treatment with 
placebo, no intervention, or another antifungal 
treatment in patients with hematologic 
malignancies. The results showed that azoles were 
associated with lower mortality compared with 
amphotericin B. Also administration of liposomal 
amphotericin B decreased the mortality and IFIs 
more than other amphotericin B formulations.34  
   Voriconazole is the first line agent for the 
treatment of aspergillosis infection35 and during our 
study it was prescribed when there was a suspicion 
of aspergillosis infection and due to the 
considerable high cost it was not used as an option 
for empiric treatment. This is the same as the study 
of Chen et al in which they found that voriconazole 
was infrequently used for empirical therapy and it 
was prescribed in 23% of all antifungal drug 
administrations. Additionally, most often it was 
used for the cases of high clinical suspicion of 
invasive aspergillosis.33  
   None of the patients in our study were proven 
cases of IFI and only in one patient the positive 
results of serum galactomannane test was available. 
So, the patients received empiric antifungal 
treatment. Although it is proposed that empiric 
treatment did not result in considerable decrease in 
mortality, it led to a signiﬁcant decrease in the 
documented or probable IFIs34 and is considered to 
be the standard practice in special patient 
populations.36 However, this approach may also 
increase the risk of overtreatment with these 
agents.8 One of the patients in our study had a 
positive serum galactomannane test. In the absence 
of stronger evidences for proving fungal infections, 
serum galactomannane test and computed 
tomography (CT) are helpful measures for the 
initiation of antifungal treatment and can predict 
response. For example Ji et al., retrospectively 
studied 124 patients who received empirical 
antifungal agents following allogeneic HSCT and 
concluded that patients with positive serum 
galactomannane test and/or chest CT scan had 
significantly higher response rate to empirical 
antifungal treatment compared with all patients.36  
   We did not observe any significant differences in 
neutropenia duration (P value: 0.54), length of 
hospital stay (P value: 0.27) and number of patients 
developed graft versus host disease (P value: 0.07) 
between patients received antifungal agents with 
those who did not receive treatment. 
 
Limitations 
   The most important restriction in our study was 
the lack of microbiologic confirmation of the IFIs in 
this center which is almost the same as most other 
centers in Iran. This led to the empirical 
administrations of antifungal drugs. Another 
limitation is the short time patients’ follow up which 
did not allow us to assess the long-term outcomes. 
Also it should be noted that the number of patients 
included in this study was limited. So it is suggested 
that researchers conduct a prospective larger trial 
for better assessment of the fungal infections and 
their treatment.  
 
CONCLUSION 
   HSCT recipients in this study received antifungal 
agents for prophylaxis of fungal infections. None of 
the patients in this study received targeted 
treatment with antifungal agents and the treatment 
was implemented empirically. Improvements in 
diagnosis of these infections can be helpful and lead 
to targeted therapy.   
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